Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Robinson, A. Sureda, C. Canals, N. Russell, D. Caballero, A. Bacigalupo, A. Iriondo, G. Cook, A. Pettitt, G. Socié, F. Bonifazi, A. Bosi, M. Michallet, E. Liakopoulou, J. Maertens, J. Passweg, F. Clarke, R. Martino, N. Schmitz (2009)Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome
A. Peniket, M. Elvira, G. Taghipour, C. Cordonnier, E. Gluckman, T. Witte, G. Santini, D. Blaise, H. Greinix, A. Ferrant, J. Cornelissen, N. Schmitz, A. Goldstone, On Registry (2003)An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
Bone Marrow Transplantation, 31
J. Gajewski, G. Phillips, K. Sobocinski, J. Armitage, R. Gale, R. Champlin, R. Herzig, D. Hurd, S. Jagannath, J. Klein, H. Lazarus, P. McCarthy, S. Pavlovsky, F. Peterson, P. Rowlings, J. Russell, S. Silver, J. Vose, P. Wiernik, M. Bortin, M. Horowitz (1996)Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 2
N. Milpied, A. Fielding, R. Pearce, P. Ernst, A. Goldstone (1996)Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 4
L. Burroughs, P. O'Donnell, B. Sandmaier, B. Storer, L. Luznik, H. Symons, Richard Jones, R. Ambinder, M. Maris, K. Blume, D. Niederwieser, B. Bruno, R. Maziarz, M. Pulsipher, F. Petersen, R. Storb, E. Fuchs, D. Maloney (2008)Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 11
B. Sirohi, D. Cunningham, R. Powles, Felicity Murphy, T. Arkenau, A. Norman, J. Oates, A. Wotherspoon, A. Horwich (2008)Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 7
A. Josting, U. Rueffer, J. Franklin, M. Sieber, Volker Diehl, A. Engert (2000)Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.
Blood, 96 4
J. Anderson, M. Litzow, F. Appelbaum, G. Schoch, L. Fisher, C. Buckner, F. Petersen, S. Crawford, O. Press, J. Sanders (1993)Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 12
L. Castagna, B. Sarina, E. Todisco, M. Magagnoli, M. Balzarotti, S. Bramanti, R. Mazza, A. Anastasia, A. Bacigalupo, F. Aversa, D. Soligo, L. Giordano, A. Santoro (2009)Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 4
K. Peggs, A. Sureda, W. Qian, D. Caballero, A. Hunter, Á. Urbano-Ispizua, J. Cavet, J. Ribera, A. Parker, M. Canales, P. Mahendra, J. Garcia-conde, D. Milligan, G. Sanz, K. Thomson, R. Arranz, A. Goldstone, Iván Alvarez, D. Linch, J. Sierra, S. Mackinnon (2007)Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes
British Journal of Haematology, 139
N. Majhail, D. Weisdorf, J. Wagner, T. Defor, C. Brunstein, L. Burns (2006)Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.
Blood, 107 9
B. Sarina, L. Castagna, L. Farina, F. Patriarca, F. Benedetti, A. Carella, M. Falda, S. Guidi, F. Ciceri, A. Bonini, S. Ferrari, M. Malagola, E. Morello, G. Milone, B. Bruno, N. Mordini, S. Viviani, A. Levis, L. Giordano, A. Santoro, P. Corradini (2008)Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.
Blood, 115 18
L. Castagna, S. Bramanti, M. Balzarotti, B. Sarina, E. Todisco, A. Anastasia, M. Magagnoli, R. Mazza, A. Nozza, L. Giordano, M. Rodari, Eva Rinifilo, A. Chiti, A. Santoro (2009)Predictive value of early 18F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high‐dose chemotherapy
British Journal of Haematology, 145
N. Bartlett, A. Younes, M. Carabasi, A. Forero, J. Rosenblatt, J. Leonard, S. Bernstein, R. Bociek, J. Lorenz, Bruce Hart, J. Barton (2008)A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
P. Anderlini, R. Saliba, S. Acholonu, S. Giralt, B. Andersson, N. Ueno, C. Hosing, I. Khouri, D. Couriel, M. Lima, M. Qazilbash, B. Pro, J. Romaguera, L. Fayad, Frederick Hagemeister, A. Younes, M. Munsell, R. Champlin (2008)Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience
Mauro Todisco (2007)Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin.
American journal of therapeutics, 14 1
K. David, L. Mauro, A. Evens (2007)Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options
Current Treatment Options in Oncology, 8
M. Devetten, P. Hari, J. Carreras, B. Logan, K. Besien, C. Bredeson, C. Freytes, R. Gale, J. Gibson, S. Giralt, S. Goldstein, Vikas Gupta, D. Marks, R. Maziarz, J. Vose, H. Lazarus, P. Anderlini (2009)Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 1
A. Sureda, S. Robinson, C. Canals, A. Carella, M. Boogaerts, D. Caballero, A. Hunter, L. Kanz, S. Slavin, J. Cornelissen, M. Gramatzki, D. Niederwieser, N. Russell, N. Schmitz (2008)Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 3
F. Appelbaum, K. Sullivan, E. Thomas, C. Buckner, R. Clift, H. Deeg, P. Neiman, J. Sanders, P. Stewart, R. Storb (1985)Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 3 11
L. Castagna, M. Magagnoli, M. Balzarotti, B. Sarina, L. Siracusano, A. Nozza, E. Todisco, S. Bramanti, R. Mazza, F. Russo, I. Timofeeva, A. Santoro (2007)Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study
American Journal of Hematology, 82
B. Klimm, R. Schnell, V. Diehl, A. Engert (2005)Current treatment and immunotherapy of Hodgkin's lymphoma.
Haematologica, 90 12
N. Schmitz, B. Pfistner, M. Sextro, M. Sieber, A. Carella, M. Haenel, F. Boissevain, R. Zschaber, P. Müller, H. Kirchner, A. Lohri, S. Decker, Bettina Koch, D. Hasenclever, A. Goldstone, V. Diehl (2002)Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
The Lancet, 359
G. Bonadonna, V. Bonfante, S. Viviani, A. Russo, F. Villani, P. Valagussa (2004)ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14
Iván Alvarez, A. Sureda, M. Caballero, Á. Urbano-Ispizua, J. Ribera, M. Canales, J. Garcia-conde, G. Sanz, R. Arranz, M. Bernal, J. Serna, J. Díez, J. Moraleda, D. Rubió-Félix, B. Xicoy, C. Martínez, M. Mateos, J. Sierra (2006)Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 2
R. Schnell, M. Dietlein, J. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, V. Diehl, A. Raubitschek, A. Engert (2005)Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 21
E. Jabbour, C. Hosing, G. Ayers, R. Nunez, P. Anderlini, B. Pro, I. Khouri, A. Younes, F. Hagemeister, L. Kwak, L. Fayad (2007)Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
K. Thomson, K. Peggs, Paul Smith, James Cavet, A. Hunter, A. Parker, R. Pettengell, Donald Milligan, Emma Morris, A. Goldstone, D. Linch, Stephen Mackinnon (2008)Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
Bone Marrow Transplantation, 41
R. Meyer, M. Gospodarowicz, J. Connors, R. Pearcey, A. Bezjak, W. Wells, B. Burns, J. Winter, S. Horning, A. Dar, M. Djurfeldt, K. Ding, L. Shepherd (2005)Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 21
J. Vose, P. Bierman, James, Anderson, A. Kessinger, J. Pierson, J. Nelson, Bettina Frappier, K. Schmit-Pokorny, D. Weisenburger, J. Armitage (1992)Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up.
Blood, 80 8
H. Pohl, A. Shimoni, N. Kroeger, Hans Martin, V. Vučinić, N. Basara, A. Nagler, A. Zander, A. Fauser, Michael Kiehl (2004)Allogeneic stem cell transplantation in patients with Hodgkin's-Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
G. Phillips, S. Wolff, R. Herzig, H. Lazarus, J. Fay, H. Lin, D. Shina, G. Glasgow, R. Griffith, C. Lamb (1989)Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation.
Blood, 73 8
R Jones, S. Piantadosi, R. Mann, R. Ambinder, E Seifter, H. Vriesendorp, M. Abeloff, W. Burns, W. May, S Rowley (1990)High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 3
Comparable results of umbilical cord
G. Bonadonna, S. Viviani, V. Bonfante, A. Gianni, P. Valagussa (2005)Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
European journal of cancer, 41 7
M. Varterasian, V. Ratanatharathorn, J. Uberti, C. Karanes, E. Abella, F. Momin, C. Kasten‐Sportès, A. Al-Katib, L. Lum, L. Heilbrun (1995)Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation.
Leukemia & lymphoma, 20 1-2
P. Anderlini, R. Saliba, S. Acholonu, G. Okoroji, M. Donato, S. Giralt, B. Andersson, N. Ueno, I. Khouri, M. Lima, C. Hosing, A. Cohen, C. Ippoliti, J. Romaguera, Maria Rodriguez, B. Pro, L. Fayad, A. Goy, Ahmed Younes (2005)Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
A. Forero-Torres, J. Leonard, A. Younes, J. Rosenblatt, P. Brice, N. Bartlett, A. Bosly, L. Pinter-Brown, D. Kennedy, E. Sievers, A. Gopal (2009)A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
British Journal of Haematology, 146
P Anderlini, R Saliba, S Acholonu (2005)Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin?s disease: low transplant-related mortality and impact of intensity of conditioning regimen
Bone Marrow Transplant, 35
G. Akpek, R. Ambinder, S. Piantadosi, R. Abrams, R. Brodsky, G. Vogelsang, M. Zahurak, D. Fuller, Carole Miller, S. Noga, E. Fuchs, I. Flinn, P. O'Donnell, E. Seifter, R. Mann, Richard Jones (2001)Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 23
A. Josting, J. Franklin, M. May, P. Koch, M. Beykirch, J. Heinz, C. Rudolph, V. Diehl, A. Engert (2002)New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 1
D. Linch, A. Goldstone, A. McMillan, R. Chopra, G. Hudson, D. Winfield, B. Hancock, D. Moir, D. Milligan (1993)Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial
The Lancet, 341
D. Duggan, G. Petroni, Jeffrey Johnson, J. Glick, R. Fisher, J. Connors, G. Canellos, B. Peterson (2003)Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 4
P. Gobbi, A. Levis, T. Chisesi, C. Broglia, U. Vitolo, C. Stelitano, V. Pavone, L. Cavanna, G. Santini, F. Merli, M. Liberati, L. Baldini, G. Deliliers, E. Angelucci, R. Bordonaro, M. Federico (2005)ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
K. Peggs, A. Hunter, R. Chopra, A. Parker, P. Mahendra, D. Milligan, C. Craddock, R. Pettengell, A. Dogan, K. Thomson, E. Morris, G. Hale, H. Waldmann, A. Goldstone, D. Linch, S. Mackinnon (2005)Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
The Lancet, 365
Although the majority of patients with Hodgkin lymphoma achieve sustained remission with frontline treatment, there is still a subset of patients with much less favorable prognosis. The current standard of care for Hodgkin lymphoma patients with relapsed or refractory disease is autologous stem cell transplantation. However, no randomized trial has compared autologous stem cell transplantation with allogeneic stem cell transplantation prospectively, and most studies comparing allogeneic stem cell transplantation with historical controls of autologous stem cell transplantation use a myeloablative conditioning reference group. With the more frequent use of reduced-intensity conditioning transplantation in recent studies, the role for allogeneic stem cell transplantation in Hodgkin lymphoma patients is being redefined. In contrast to other types of lymphomas, Hodgkin lymphoma patients are younger at diagnosis, which makes a curative strategy such as allogeneic stem cell transplantation particularly appealing. This review examines the role of allogeneic stem cell transplantation in Hodgkin lymphoma by looking at both retrospective and prospective analyses in the era of reduced-intensity conditioning transplantation, donor lymphocyte infusions, and biologically based treatments.
Current Hematologic Malignancy Reports – Springer Journals
Published: Aug 21, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.